Pharmaceutically acceptable salt as renal outer medullary potassium channel inhibitor
US11059810B2 · kind B2 · utility
0Cited by
3References
6Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 6, 2017 |
| Grant date | Jul 13, 2021 |
| Priority date | — |
| Expiry date | Jul 2, 2037 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P9/12
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A pharmaceutically acceptable salt as a renal outer medullary potassium channel (ROMK) inhibitor, specifically an L-tartrate and a crystal form I and crystal form II thereof, is described. The pharmaceutically acceptable salt of the ROMK inhibitor, specifically the L-tartrate, has improved bioavailability and stability.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.